MERIT is your clinical endpoint expert. We partner with CROs, pharmaceutical, and biotech companies to deliver reliable endpoint services in global clinical trials. Together our work advances and accelerates the improvement of therapeutic options for patients worldwide. ...
How You Can Support GBM AGILE Be a partner for one of our Australian trial sites and help ensure the future of this trial for years to come. When you are a champion of this groundbreaking research, you are helping provide these innovative trials and support for GBM patients and Australian...
This review describes considerations in designing future GBM clinical trials in not only immunotherapy but also with other promising treatments. We will discuss factors, such as pseudoprogression, genetic and circulating biomarkers, and the commensal microbiome of patients in the setting of clinical trial...
23]. Currently, only olaratumab has successfully progressed to clinical trials for GBM (Table1). Despite its therapeutic potential in pre-clinical models of GBM, olaratumab showed minimal clinical efficacy in GBM patients
Many clinical trials examining the clinical potential of miRNAs as biomarkers for cancer therapy response prediction, diagnosis, and prognostication are underway. As diagnostic markers, miRNAs in blood or tissue samples from cancer patients have been tested. A few clinical trials of diagnostic miRNAs we...
The pattern of the basket, umbrella, and platform trial design. The basket trials aim to evaluate the efficacy of a certain biomarker in multiple diseases or different tissue types (such as cancer). Recruitment is completed by screening patients with the same therapeutic target through next-generat...
Recent large phase III trials of novel treatment approaches failed to improve survival of patients with newly diagnosed GBM. Dose intensification of the adjuvant or maintenance TMZ therapy [36], the addition of cilengitide [37] or the addition of bevacizumab [38,39] did not translate into prolong...
This potentially pivotal, global study of Berubicin is an adaptive, multicenter, open-label, randomized controlled study in adult patients with recurrent GBM (WHO Grade IV) after failure of standard first-line therapy and compared...
Many clinical trials are designed for patients with advanced cancer who have received standard-of-care treatment. These patients are typically older due to rising life expectancy and may have age-related medical conditions that worsen their PS, in addition to the cumulative ef...
Traditional oncology practice relies on average-population-benefit decisions, often derived from randomized clinical trials of unselected patients, which have been the cornerstone of drug approvals for decades [1,2]. Customarily, therapy decisions were based on the tumor organ of origin, and this ...